JP2023507852A5 - - Google Patents

Info

Publication number
JP2023507852A5
JP2023507852A5 JP2022538756A JP2022538756A JP2023507852A5 JP 2023507852 A5 JP2023507852 A5 JP 2023507852A5 JP 2022538756 A JP2022538756 A JP 2022538756A JP 2022538756 A JP2022538756 A JP 2022538756A JP 2023507852 A5 JP2023507852 A5 JP 2023507852A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
composition according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022538756A
Other languages
English (en)
Japanese (ja)
Other versions
JP7734673B2 (ja
JP2023507852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065924 external-priority patent/WO2021133660A1/en
Publication of JP2023507852A publication Critical patent/JP2023507852A/ja
Publication of JP2023507852A5 publication Critical patent/JP2023507852A5/ja
Application granted granted Critical
Publication of JP7734673B2 publication Critical patent/JP7734673B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538756A 2019-12-23 2020-12-18 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法 Active JP7734673B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962952971P 2019-12-23 2019-12-23
US62/952,971 2019-12-23
US202063007489P 2020-04-09 2020-04-09
US63/007,489 2020-04-09
US202062704879P 2020-06-01 2020-06-01
US62/704,879 2020-06-01
PCT/US2020/065924 WO2021133660A1 (en) 2019-12-23 2020-12-18 Methods of treating pregnancy-associated atypical hemolytic uremic syndrome using an anti-c5 antibody

Publications (3)

Publication Number Publication Date
JP2023507852A JP2023507852A (ja) 2023-02-27
JP2023507852A5 true JP2023507852A5 (https=) 2023-12-21
JP7734673B2 JP7734673B2 (ja) 2025-09-05

Family

ID=74184931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538756A Active JP7734673B2 (ja) 2019-12-23 2020-12-18 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法

Country Status (4)

Country Link
US (1) US20230043576A1 (https=)
EP (1) EP4081805A1 (https=)
JP (1) JP7734673B2 (https=)
WO (1) WO2021133660A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
WO2014099546A1 (en) 2012-12-19 2014-06-26 Promerus, Llc Process for the preparation of high purity norbornene alkanols and derivatives thereof
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
CN118512588A (zh) 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients

Similar Documents

Publication Publication Date Title
JP2021526534A5 (https=)
JP2021501134A5 (https=)
WO2020097099A1 (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
JP2022518507A5 (https=)
JP2021525718A5 (https=)
JP2024532831A (ja) アクチビン受容体ｉｉ型シグナル伝達阻害剤を使用する方法
JP2023533030A5 (https=)
AU2017201771A1 (en) Methods and compositions for treating lupus
JP5220315B2 (ja) 抗ＥｐＣＡＭ免疫グロブリン
EP4467566A2 (en) Pan elr+ cxc chemokine antibodies
CA3187866A1 (en) Inflammatory cytokines and fatigue in subject with a complement mediated disease
JP2023533682A5 (https=)
JP7317827B2 (ja) 腎線維症および／または慢性腎臓疾患の治療におけるＦＸＩＩａインヒビターの使用
JP2023545432A5 (https=)
JP2023539047A5 (https=)
JP2024540480A5 (https=)
JP2023507852A5 (https=)
JP2018533588A (ja) 治療パラダイム
KR20230142834A (ko) 항-cd38 항체 및 이의 용도
JP2025528527A (ja) 抗ＦｃＲＮ抗体を用いたグレーブス病の治療方法
US20230399405A1 (en) Vista agonist for treatment/prevention of ischemic and/or reperfusion injury
CN113993543B (zh) 使用抗cd38抗体的组合疗法
RU2021125057A (ru) ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС)
TWI886758B (zh) 抗pvrig/抗tigit雙特異性抗體在治療惡性腫瘤中的用途
RU2024117500A (ru) Дозы и введение антител против c5 для лечения атипичного гемолитико-уремического синдрома (агус)